For years, hormone therapy (HT) was considered a panacea for women adjusting to the changes of menopause and for preventive health. Despite a clear benefit for bone health, HT poses other risks for some women, including heart attack, stroke, breast cancer, and blood clots. Because of these serious risks, HT is no longer being used for the treatment of bone loss or fracture prevention.
The current recommendations for women are to take the lowest HT dose possible for the shortest period of time for symptoms associated with menopause. Your healthcare provider can share the risks and benefits and it is important to review the pros and cons annually. The North American Menopause Society has more information about HT.
HT is administered in several forms including oral or transdermal, gels and lotions including: Premarin®, Estrace®, Ogen®, Cenestin®, Climara®, Vivelle-Dot®, Menostar®, and others.
HT is associated with a slightly increased risk of heart attack, breast cancer, stroke, and blood clots.